Q-omics provides the consensus-scored RPS27P20 profile across patient tissues and cancer cell-line models. RPS27P20 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RPS27P20 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, RPS27P20 RNA expression shows 3,681 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight COAD, HNSC, and BRCA as cancer lineages where RPS27P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27P20 survival associations across molecular data types. RPS27P20 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27P20 RNA expression–survival associations across cancer types. High RPS27P20 expression shows unfavorable associations in ACC, TGCT, HNSC and PCPG, but favorable associations in COAD and LUAD. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify COAD as the clearest survival context for RPS27P20 RNA expression.
This table summarizes RPS27P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS27P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27P20 shows lower tumor expression in HNSC and higher tumor expression in LUAD. The HNSC box plot shows higher RPS27P20 RNA expression in normal versus tumor tissue (log2 FC = −0.064, t-test p = .015).
This table shows molecular features associated with RPS27P20 in patient tissues and cancer cell lines. In patient samples, RPS27P20 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
